White Mountain Eye Institute Plc Medicare Supplier Location: 39 E 1st St, Eagar, Arizona 85925 Phone: (928) 333-4396 |
News Archive
Respicardia®, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the U.S. Healthcare Product of the Year by Acquisition International for the remede System, the first and only implantable device for the treatment of central sleep apnea.
A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.
The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment.
Systagenix announced today the launch and sponsorship of a new wound care educational e-learning programme for qualified medical professionals entering the field of wound care and experienced specialist nurses.
› Verified 7 days ago